Here are relevant reports on : Pharmaceutical-Drug Delivery Market
-
Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022
The protein assays market is projected to reach USD 2.41 Billion by 2022, at a CAGR of 11.1%. Some of the prominent players in the market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).
- Published: May 2017
- Price: $ 4950
- TOC Available:
-
Electronic Trial Master File (eTMF) Systems Market by Component (Services, Software), End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations), Delivery Mode (On-Premise, Cloud-Based), and Region - Global Forecast to 2024
The Electronic Trial Master File (eTMF) Systems Market is expected to grow from USD 1.0 billion in 2019 to USD 1.8 billion by 2024, at a CAGR of 12.7% during the forecast period. Veeva Systems (US), Oracle Corporation (US), Phlexglobal Limited (UK), TransPerfect Global Inc. (US), Aurea Software (US), LabCorp (US), ePharmaSolutions (US), Wingspan Technology, Inc. (US), MasterControl (US), SureClinical, Inc. (US), Dell EMC (US), Paragon Solutions (US), PharmaVigilant (US), Mayo Clinic (US), Database Integrations, Inc. (US), CareLex (US), Ennov (France), Forte Research (US), Freyr (US), Montrium (US), NCGS Inc. (US), SAFE-BioPharma (US), SterlingBio Inc. (US), BIOVIA Corp. (US), and arivis AG (Germany) are the key players in the eTMF systems market.
- Published: August 2019
- Price: $ 4950
- TOC Available:
-
CRISPR Market by Product Type (Plasmids, Vectors, CAS9 Nuclease & GRNA, Delivery System), Application (Genetic Engineering, Cell Engineering) & End User (Biotechnology & Pharmaceutical Companies, Contract Research Organization) - Global Forecast to 2023
The global CRISPR market is expected to reach USD 4.16 billion by 2023 from USD 2.01 billion in 2018, growing at a CAGR of 15.7%. Increasing incidences and prevalence of genetic disorders, rising government funding on genomic research, increasing production of genetically modified crops and increasing demand for drug discovery are some of the major factors driving the growth of the global CRISPR market.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & marketing, Drug Safety), End User (Pharma, Medical Device), & Region - Global Forecast to 2029
The global life science analytics market, valued at US$31.78B in 2023, is forecasted to grow at a 11.7% CAGR, reaching US$35.69B by 2024 and US$61.94B by 2029. The growing focus on quality control, regulatory compliance, developed healthcare & life sciences infrastructure, and the surging demand for digitalized technologies across North America further propels the growth.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Drug Screening Market Size by Product (Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Urine, Breath, Hair), Drug (Alcohol, Cannabis, Opioids), End User (Workplace, Hospital, Law) - Global Forecast to 2029
The global drug screening market, valued at US$7.7B in 2023, is forecasted to grow at a 16.6% CAGR, reaching US$9.1B by 2024 and US$19.5B by 2029. Bans on alcohol consumption in Islamic countries may restrain the growth of this market to a certain extent.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti–Epileptic Drugs,Anti–Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
The global therapeutic drug monitoring market, valued at US$2.14B in 2023, is forecasted to grow at a 8.4% CAGR, reaching US$2.30B by 2024 and US$3.44B by 2029. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Chemoinformatics Market by Application (Chemical Analysis (Chemical Databases, Chemo Metrics, Molecular Modelling), Drug Discovery (High Throughput Screening, Lead Identification and Optimization, QSAR/QSPR), Drug Validation) - Global Forecast to 2023
Growth of the chemoinformatics market is primarily driven by innovations and advancements in the drug development process, advances in the computer technology, increased demand of personalized medicine. On the other hand, cost associated with the chemoinformatics software is one of the major factors restraining the growth of this market. Whereas emerging markets are expected to provide significant growth opportunities in this market.
- Published: May 2025
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
